Speaking at the 27th St. Petersburg International Economic Forum (SPIEF), Murashko added that the brand-new vaccine is now undergoing preclinical studies, the first results of which are expected by the end of the year, before moving on to clinical trials.

Murashko also explained the vaccine was developed jointly by several scientific teams, including the Gamaleya National Research Center for Epidemiology and Microbiology, the Herzen Oncology Research Institute in Moscow and the Blokhin Cancer Research Center.

pll/mem/gfa